Back to results
US 12,560,609 B2Granted
Biomarkers predictive of cancer cell response to ML329 or a derivative thereof
AssigneesDana-Farber Cancer Institute, Inc., The General Hospital Corporation, University of Kansas
InventorsRizwan Haq, David Fisher, Frank Schoenen
Life of this patent
Estimating the term…
Abstract
The present invention is based in part on the identification of biomarkers, including NQO1, NRF2 and KEAP1, predictive of cancer cell responsiveness to treatment with ML 329 or a derivative thereof.
Claims12
A method of treating a cancer in a subject likely to be responsive to 4-[(1,4-dioxo-1,4-dihydronapthalen-2-yl)amino]benzenesulfonamide (ML329) or an ML329 derivative selected from:
- the method comprising:
- i) selecting the subject likely to be responsive to ML329 or the ML329 derivative, the subject having been identified by
- determining the presence of a KEAP1 loss-of-function mutation in cancer cells from the subject
- wherein the presence of the kelch-like ECH-associated protein 1 (KEAP1) loss-of-function mutation identifies the subject as likely to be responsive to ML329 or the ML329 derivative;
- and
- ii) administering ML329 or the ML329 derivative to the selected subject.
3 more elements
Dependencies are inferred from the claim text.